GlassScriptPhysician profile
Katie Litteken
NPI 1447598560
$1,806.75
in general payments reported to CMS, 2019-2025
28 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.20 · 2023: $967 · 2024: $468 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.13 |
| Education | $229.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $368.29 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $139.38 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $120.79 | 2025 | Myrisk |
| Merck Sharp & Dohme LLC | $110.22 | 2023-2024 | Keytruda, Welireg |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Daiichi Sankyo INC. | $96.09 | 2023-2024 | Enhertu, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $74.62 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Stemline Therapeutics INC. | $73.47 | 2023-2025 | Orserdu |
| Eisai INC. | $66.65 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $61.40 | 2022-2025 | Opdivo |
| Sun Pharmaceutical Industries INC. | $61.26 | 2023-2025 | Yonsa, Odomzo |
| Janssen Biotech, INC. | $57.92 | 2023-2025 | Rybrevant, Balversa, Erleada |
| Incyte Corporation | $53.57 | 2023 | Pemazyre, Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $50.59 | 2023-2024 | Exkivity, Fruzaqla |
| Glaxosmithkline, LLC. | $49.50 | 2023-2025 | Ojjaara |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $39.42 | 2023 | Xpovio |
| Apellis Pharmaceuticals, INC. | $36.25 | 2023 | Empaveli |
| Abbvie INC. | $33.61 | 2023-2024 | |
| Pfizer INC. | $28.50 | 2023 | |
| Immunogen, INC. | $27.48 | 2023 | Elahere |
| Blueprint Medicines Corporation | $25.36 | 2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.11 | 2024 | Gilotrif |
| Acrotech Biopharma INC. | $21.59 | 2024 | Beleodaq |
| Adc Therapeutics America, INC. | $20.91 | 2024 | |
| Emd Serono, INC. | $18.71 | 2023 | Bavencio |
| Cti Biopharma Corp. | $18.28 | 2023 | Vonjo |
| Regeneron Healthcare Solutions, INC. | $18.03 | 2023 | Libtayo |
| Amgen INC. | $12.80 | 2023 | Kyprolis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Litteken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.